Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data

por Bota, Daniela A, Mason, Warren, Kesari, Santosh, Magge, Rajiv, Winograd, Benjamin, Elias, Ileana, Reich, Steven D, Levin, Nancy, Trikha, Mohit, Desjardins, Annick
Publicado 2021

Evaluating imbalances of adverse events during biosimilar development

por Vana, Alicia M., Freyman, Amy W., Reich, Steven D., Yin, Donghua, Li, Ruifeng, Anderson, Scott, Jacobs, Ira A., Zacharchuk, Charles M., Ewesuedo, Reginald
Publicado 2016

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients

por Levin, Nancy, Spencer, Andrew, Harrison, Simon J., Chauhan, Dharminder, Burrows, Francis J., Anderson, Kenneth C., Reich, Steven D., Richardson, Paul G., Trikha, Mohit
Publicado 2016

First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors

por Shapiro, Geoffrey I., Vaishampayan, Ulka N., LoRusso, Patricia, Barton, Jeremy, Hua, Steven, Reich, Steven D., Shazer, Ronald, Taylor, Carrie T., Xuan, Dawei, Borghaei, Hossein
Publicado 2017